Clinical Trials Browser

Phase 2/3 × OTHER × tegafur-gimeracil-oteracil × Clear all

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Phase 2/3 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT01704690 2017-04-07

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

Phase 2/3 Terminated

Gastrointestinal

Esophageal Neoplasms